ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $21.39 to $22.26
• 50-Day Range: $14.35 to $22.95
• 52-Week Range: $13.40 to $25.23
• Volume: 665,329 shs
• Average Volume: 1.96 million shs
• Market Capitalization: $3.58 billion
• P/E Ratio: 15.64
• Dividend Yield: N/A
• Price Target: $27.88
• Consensus Rating: Moderate Buy

ACADIA Pharmaceuticals Stock Analysis - MarketRank™

ACADIA Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 88th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ACADIA Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.57%

Earnings Growth

Earnings for ACADIA Pharmaceuticals are expected to grow by 8.57% in the coming year, from $0.70 to $0.76 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ACADIA Pharmaceuticals is 15.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of ACADIA Pharmaceuticals is 15.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.49.

Price to Earnings Growth Ratio

ACADIA Pharmaceuticals has a PEG Ratio of 4.77. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ACADIA Pharmaceuticals has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.55% of the float of ACADIA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in ACADIA Pharmaceuticals has recently decreased by 7.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ACADIA Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ACADIA Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.55% of the float of ACADIA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in ACADIA Pharmaceuticals has recently decreased by 7.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.69

News Sentiment

ACADIA Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for ACADIA Pharmaceuticals this week, compared to 9 articles on an average week.

Search Interest

11 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $580,446.00 in company stock.

Percentage Held by Insiders

26.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACAD Stock Analysis - Frequently Asked Questions

How have ACAD shares performed this year?

ACADIA Pharmaceuticals' stock was trading at $18.35 at the beginning of the year. Since then, ACAD shares have increased by 17.6% and is now trading at $21.58.
View the best growth stocks for 2025 here.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Wednesday, May, 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The company's revenue was up 18.7% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACAD
• CIK: 1070494
• Web: www.acadia-pharm.com
• Phone: (858) 558-2871
• Fax: 858-558-2872
• Employees: 510
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $27.88
• High Stock Price Target: $38.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +28.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 17 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.37
• Trailing P/E Ratio: 15.82
• Forward P/E Ratio: 30.97
• P/E Growth: 4.77
• Net Income: $226.45 million
• Net Margins: 22.97%
• Pretax Margin: 26.58%
• Return on Equity: 17.46%
• Return on Assets: 10.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 2.80

Sales & Book Value

• Annual Sales: $996.28 million
• Price / Sales: 3.64
• Cash Flow: $0.69 per share
• Price / Cash Flow: 31.38
• Book Value: $4.40 per share
• Price / Book: 4.93

Miscellaneous

• Outstanding Shares: 167,362,000
• Free Float: 119,999,000
• Market Cap: $3.63 billion
• Optionable: Optionable
• Beta: 0.65